Mitofusin 2 inhibits bladder cancer cell proliferation and invasion via the Wnt/β‑catenin pathway

Pang,Guofu; Xie,Qun; Yao,Juanjuan

doi:10.3892/ol.2019.10570

Mitofusin 2 inhibits bladder cancer cell proliferation and invasion via the Wnt/β‑catenin pathway

Authors:
- Guofu Pang
- Qun Xie
- Juanjuan Yao
View Affiliations

Affiliations: Department of Urology, Zhuhai People's Hospital, Zhuhai, Guangdong 519000, P.R. China
Published online on: July 5, 2019 https://doi.org/10.3892/ol.2019.10570
Pages: 2434-2442
Copyright: © Pang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the biological role of the mitochondrial GTPase mitofusin‑2 (MFN2) in bladder cancer. MFN2 mRNA expression in tumor and paired adjacent non‑tumor tissues from 8 patients was investigated using reverse transcription‑quantitative polymerase chain reaction analysis. Immunohistochemistry was used to investigate MFN2 expression in 117 bladder cancer specimens. The associations of MFN2 expression with clinicopathological parameters were evaluated statistically. In addition, the biological role of MFN2 in the proliferation, migration and invasion of bladder cancer cells was examined. It was identified that MFN2 expression was significantly downregulated in bladder cancer tissues compared with normal tissues. MFN2 expression was associated with tumor stage, tumor grade and lymph node status. Furthermore, patients with low MFN2 expression demonstrated a shorter overall survival time (P=0.025). MFN2 knockdown by small interfering RNA promoted cancer cell proliferation, migration and invasion in vitro, and enhanced tumor progression in vivo. Mechanistically, MFN2 was revealed to be involved in Wnt/β‑catenin signaling. In conclusion, MFN2 may serve as a potential therapeutic target in the treatment of bladder cancer, and the progress of bladder cancer may be delayed by regulating MFN2 expression.

View Figures

View References

1	Popovic LS, Matovina-Brko G and Popovic M: Checkpoint inhibitors in the treatment of urological malignancies. ESMO open. 2:e0001652017. View Article : Google Scholar : PubMed/NCBI
2	Siddiqui MR, Grant C, Sanford T and Agarwal PK: Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol. 35:516–527. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zlatev DV, Altobelli E and Liao JC: Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am. 42147–157. (vii)2015. View Article : Google Scholar : PubMed/NCBI
4	Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M and Horwich A; ESMO Guidelines Working Group, : Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii40–iii48. 2014. View Article : Google Scholar : PubMed/NCBI
5	Papanicolaou KN, Kikuchi R, Ngoh GA, Coughlan KA, Dominguez I, Stanley WC and Walsh K: Mitofusins 1 and 2 are essential for postnatal metabolic remodeling in heart. Circulation research. 111:1012–1026. 2012. View Article : Google Scholar : PubMed/NCBI
6	Chan DC: Mitochondria: Dynamic organelles in disease, aging, and development. Cell. 125:1241–1252. 2006. View Article : Google Scholar : PubMed/NCBI
7	Guo X, Chen KH, Guo Y, Liao H, Tang J and Xiao RP: Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res. 101:1113–1122. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, et al: Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 278:17190–17197. 2003. View Article : Google Scholar : PubMed/NCBI
9	Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, et al: Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 36:449–451. 2004. View Article : Google Scholar : PubMed/NCBI
10	Xu K, Chen G, Li X, Wu X, Chang Z, Xu J, Zhu Y, Yin P, Liang X and Dong L: MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep. 7:417182017. View Article : Google Scholar : PubMed/NCBI
11	Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q and Yu JR: Anti-tumor effects of Mfn2 in gastric cancer. Int J Mol Sci. 14:13005–13021. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wang G and McKenney JK: Urinary Bladder Pathology: World Health Organization (WHO) Classification and American Joint Committee on Cancer (AJCC) Staging Update. Arch Pathol Lab Med. 143:571–577. 2018. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Cui Y, Ma W, Lei F, Li Q, Su Y, Lin X, Lin C, Zhang X, Ye L, Wu S, et al: Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/beta-catenin signalling. J Pathol. 239:297–308. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chen G, Liu N, Zhou A, Tang C, Ma D and Tang J: The role of hypertension-related gene in aortic vascular smooth muscle cells from mice and rats. Chin Med J (Engl). 114:833–836. 2001.PubMed/NCBI
16	Cao YL, Meng S, Chen Y, Feng JX, Gu DD, Yu B, Li YJ, Yang JY, Liao S, Chan DC and Gao S: MFN1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion. Nature. 542:372–376. 2017. View Article : Google Scholar : PubMed/NCBI
17	Abdelwahid E, Li H, Wu J, Irioda AC, de Carvalho KA and Luo X: Endoplasmic reticulum (ER) stress triggers Hax1-dependent mitochondrial apoptotic events in cardiac cells. Apoptosis. 21:1227–1239. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chen Y and Dorn GW II: PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science. 340:471–475. 2013. View Article : Google Scholar : PubMed/NCBI
19	Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J, Chen G and Zheng S: Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol. 28 (Suppl 1):S373–S380. 2011. View Article : Google Scholar : PubMed/NCBI
20	Wang W, Xie Q, Zhou X, Yao J, Zhu X, Huang P, Zhang L, Wei J, Xie H, Zhou L and Zheng S: Mitofusin-2 triggers mitochondria Ca2+ influx from the endoplasmic reticulum to induce apoptosis in hepatocellular carcinoma cells. Cancer Lett. 358:47–58. 2015. View Article : Google Scholar : PubMed/NCBI
21	Lou Y, Li R, Liu J, Zhang Y, Zhang X, Jin B, Liu Y, Wang Z, Zhong H, Wen S and Han B: Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. Med Oncol. 32:1322015. View Article : Google Scholar : PubMed/NCBI
22	Feng X, Zhu K, Liu J, Chen J, Tang J, Liang Y, Jin R, Liang X and Cai X: The evaluative value of Sema3C and MFN2 co-expression detected by immunohistochemistry for prognosis in hepatocellular carcinoma patients after hepatectomy. Onco Targets Ther. 9:3213–3221. 2016.PubMed/NCBI
23	Fang CL, Sun DP, Chen HK, Lin CC, Hung ST, Uen YH and Lin KY: Overexpression of Mitochondrial GTPase MFN2 represents a negative prognostic marker in human gastric cancer and its inhibition exerts anti-cancer effects. J Cancer. 8:1153–1161. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhou X, Zhang L, Zheng B, Yan Y, Zhang Y, Xie H, Zhou L, Zheng S and Wang W: MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2. Cancer Sci. 107:424–432. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ma LI, Chang Y, Yu L, He W and Liu Y: Pro-apoptotic and anti-proliferative effects of mitofusin-2 via PI3K/Akt signaling in breast cancer cells. Oncol Lett. 10:3816–3822. 2015. View Article : Google Scholar : PubMed/NCBI